Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom

We examined 56 normoprolactinemic women of reproductive age (18-45 y.o.) with isolated hypogonadotropic hypogonadism (group 1) initially and on treatment with 2 mg of 17beta-estradiol and 10 mg of dydrogesterone in sequenced manner (HRT), duration of HRT was from 18 to 42 (median 36) months; 45 heal...

Full description

Bibliographic Details
Format: Article
Language:English
Published: Endocrinology Research Centre 2010-03-01
Series:Ожирение и метаболизм
Subjects:
Online Access:https://endojournals.ru/index.php/omet/article/view/5279
id doaj-baa0be55336a4320bb01512c32686779
record_format Article
spelling doaj-baa0be55336a4320bb01512c326867792021-10-02T14:14:16ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242010-03-0171525710.14341/2071-8713-52795237Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmomWe examined 56 normoprolactinemic women of reproductive age (18-45 y.o.) with isolated hypogonadotropic hypogonadism (group 1) initially and on treatment with 2 mg of 17beta-estradiol and 10 mg of dydrogesterone in sequenced manner (HRT), duration of HRT was from 18 to 42 (median 36) months; 45 healthy women (20-38 y.o.) were included in control group 2. Initially hypercholesterolemia was observed in 50% of cases in group 1 and 6.6% in group 2 (z=12,29, p=0,0005); nevertheless, the difference in lipid levels between groups 1 and 2 was not statistically significant: total cholesterol levels 5,2 (4,3; 6,0) mmol/l and 4,63 (4,15; 5,15) mmol/l respectively (1vs2, р=0,1); triglycerides 0,8 (0,62; 1,3) mmol/l and 0,76 (0,6; 0,85) mmol/l (1vs2, р=0,08); HDL 1,89 (1,24; 2,1) mmol/l and 1,79 (1,44; 2,8) mmol/l (1vs2, p=0,85); LDL 2,7 (2,2; 3,2) mmol/l and 2,75 (2,3; 3,3) mmol/l (1vs2, p=0,64). In group 1 decrease of total cholesterol and triglycerides concentrations was found on HRT: total cholesterol 4,8 (3,95; 5,1) mmol/l (before vs on treatment p=0,041), triglycerides 0,65 (0,6; 0,9) (before vs on treatment p=0,044) respectively, changes in HDL and LDL levels were not revealed. Initial concentrations of Ca++, P, and alkaline phosphatase (AP) were within normal range in all women. However, concentrations of Ca++ and AP were higher in group 1 compared to group 2: Ca++ 1,13 (1,08; 1,19) mmol/l and 1,05 (1,03; 1,09) mmol/l (1vs2, p=0,0016); AP 161,5 (141,8; 183) IU/l and 141,0 (119; 151) IU/l (1vs2, p=0,044). On HRT reduce in Ca++ and AP concentrations was observed: Ca++ concentrations 1,05 (1,03; 1,10) mmol/l (before vs on treatment p=0,004), AP 139 (112; 143) IU/l (before vs on treatment p=0,004). HRT was accompanied by improvement of clinical symptoms, had no influence on thyroid function, and provoked physiological rise of prolactin levels.Thus, despite lacking the expressed biochemical disorders, isolated hypogonadotropic hypogonadism in women of reproductive age have hidden negative impact on lipid and mineral metabolism. Long term HRT is safe and significantly improved parameters of lipid and mineral homeostasis in this cohort of patients.https://endojournals.ru/index.php/omet/article/view/5279гипогонадотропный гипогонадизм у женщинлипидный обменминеральный обмензаместительная гормональная терапия
collection DOAJ
language English
format Article
sources DOAJ
title Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
spellingShingle Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
Ожирение и метаболизм
гипогонадотропный гипогонадизм у женщин
липидный обмен
минеральный обмен
заместительная гормональная терапия
title_short Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
title_full Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
title_fullStr Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
title_full_unstemmed Effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
title_sort effekty dlitel'nogo primeneniya estrogen-gestagennoy terapii u zhenshchin reproduktivnogovozrasta s izolirovannym gipogonadotropnymgipogonadizmom
publisher Endocrinology Research Centre
series Ожирение и метаболизм
issn 2071-8713
2306-5524
publishDate 2010-03-01
description We examined 56 normoprolactinemic women of reproductive age (18-45 y.o.) with isolated hypogonadotropic hypogonadism (group 1) initially and on treatment with 2 mg of 17beta-estradiol and 10 mg of dydrogesterone in sequenced manner (HRT), duration of HRT was from 18 to 42 (median 36) months; 45 healthy women (20-38 y.o.) were included in control group 2. Initially hypercholesterolemia was observed in 50% of cases in group 1 and 6.6% in group 2 (z=12,29, p=0,0005); nevertheless, the difference in lipid levels between groups 1 and 2 was not statistically significant: total cholesterol levels 5,2 (4,3; 6,0) mmol/l and 4,63 (4,15; 5,15) mmol/l respectively (1vs2, р=0,1); triglycerides 0,8 (0,62; 1,3) mmol/l and 0,76 (0,6; 0,85) mmol/l (1vs2, р=0,08); HDL 1,89 (1,24; 2,1) mmol/l and 1,79 (1,44; 2,8) mmol/l (1vs2, p=0,85); LDL 2,7 (2,2; 3,2) mmol/l and 2,75 (2,3; 3,3) mmol/l (1vs2, p=0,64). In group 1 decrease of total cholesterol and triglycerides concentrations was found on HRT: total cholesterol 4,8 (3,95; 5,1) mmol/l (before vs on treatment p=0,041), triglycerides 0,65 (0,6; 0,9) (before vs on treatment p=0,044) respectively, changes in HDL and LDL levels were not revealed. Initial concentrations of Ca++, P, and alkaline phosphatase (AP) were within normal range in all women. However, concentrations of Ca++ and AP were higher in group 1 compared to group 2: Ca++ 1,13 (1,08; 1,19) mmol/l and 1,05 (1,03; 1,09) mmol/l (1vs2, p=0,0016); AP 161,5 (141,8; 183) IU/l and 141,0 (119; 151) IU/l (1vs2, p=0,044). On HRT reduce in Ca++ and AP concentrations was observed: Ca++ concentrations 1,05 (1,03; 1,10) mmol/l (before vs on treatment p=0,004), AP 139 (112; 143) IU/l (before vs on treatment p=0,004). HRT was accompanied by improvement of clinical symptoms, had no influence on thyroid function, and provoked physiological rise of prolactin levels.Thus, despite lacking the expressed biochemical disorders, isolated hypogonadotropic hypogonadism in women of reproductive age have hidden negative impact on lipid and mineral metabolism. Long term HRT is safe and significantly improved parameters of lipid and mineral homeostasis in this cohort of patients.
topic гипогонадотропный гипогонадизм у женщин
липидный обмен
минеральный обмен
заместительная гормональная терапия
url https://endojournals.ru/index.php/omet/article/view/5279
_version_ 1716854670840823808